Curadigm, a wholly-owned subsidiary of Nanobiotix S.A., incorporated in France and will aim to expand treatment benefits by increasing drug bioavailability while decreasing unintended off-target effects, specifically liver and spleen toxicities.

The Curadigm platform is being developed for use across multiple therapeutic classes to utilize biocompatible nanoparticles to transiently occupy the pathway responsible for therapeutic clearance and hepatic toxicity.

The Curadigm platform is dedicated to bringing broadly applicable delivery technologies to patients to increase efficacy in both current & novel therapeutics and improve patient outcomes.


Visit our website